Symbol="IVVD"
AssetType="Common Stock"
Name="Invivyd Inc."
Description="Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts."
CIK="1832038"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="303 WYMAN STREET, SUITE 300, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="152180000"
EBITDA="-163608000"
PERatio="None"
PEGRatio="None"
BookValue="2.989"
DividendPerShare="0"
DividendYield="0"
EPS="-1.68"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.226"
ReturnOnEquityTTM="-0.448"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.68"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.499"
EVToRevenue="-"
EVToEBITDA="0.821"
Beta="None"
num_52WeekHigh="4.9"
num_52WeekLow="0.98"
num_50DayMovingAverage="1.321"
num_200DayMovingAverage="1.948"
SharesOutstanding="109482000"
DividendDate="None"
ExDividendDate="None"
symbol="IVVD"
open="1.41"
high="1.42"
low="1.35"
price="1.37"
volume="84080.00"
latest_trading_day="2023-07-18"
previous_close="1.39"
change="-0.02"
change_percent="-1.4388%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="68"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="32"
Volume_recent_avg="317692"
Change_recent_avg="-0.01"
Delta_recent_avg="0.13"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.74"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="32"
Aroon_momentum_negative="68"
image_negative_thumbnail_id_1="167"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0009.jpeg"
image_negative_thumbnail_id_2="1162"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0196.jpeg"
image_neutral_thumbnail_id_1="557"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_neutral_thumbnail_id_2="569"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_positive_thumbnail_id_1="623"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0085.jpeg"
image_positive_thumbnail_id_2="996"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0158.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
